SER Stock — Serina Therapeutics Inc.: Cash, EV, Pipeline

Share price

$2.25

Market cap

$57.2M

Cash

$23.0M

Enterprise value

$34.2M

Balance sheet

Cash	$23.0M
Debt	$0.0M
Net cash	$23.0M
Enterprise value	$34.2M
Basic shares	25.4M shares
Fully diluted shares	34.2M shares
Fully diluted market cap	$77.0M
Cash per share	$0.91

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SER daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Mar 14 - Apr 25	SER-252 (PEOZ-apomorphine)	Phase 1	PARKINSON DISEASE (Disorder); Advanced Parkinson's Disease	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

SER-252

Phase 1 · Active Modality: polymer conjugate

Aliases POZ-apomorphine

Target dopamine receptor

Indications

Advanced Parkinson's disease (Phase 1)

Status note Lead product candidate; POZ-modified apomorphine. FDA cleared IND Jan 2026; Phase 1b registrational study in advanced Parkinson's disease initiated with first patient dosed Feb 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	SER-252 (PEOZ-apomorphine)
Lead indication	PARKINSON DISEASE (Disorder)
Lead phase	Phase 1
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07422675	Phase 1	Recruiting	Sponsor	Serina Therapeutics	—	PARKINSON DISEASE (Disorder); Advanced Parkinson's Disease	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Serina Therapeutics on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

SER — Serina Therapeutics Inc.